Roberto González-Pizarro

Roberto González-Pizarro

Auto-generated profile, based on publicly available information

Roberto González-Pizarro

National Drug Agency Department (ANAMED), Institute of Public Health (ISP). Chile

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 May 2020 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
PDF file
ELElena Sánchez López
Elena Sánchez López
AMAna Laura Lopez Machado
Ana Laura Lopez Machado
LVLorena Bonilla Vidal
Lorena Bonilla Vidal
RGRoberto González-Pizarro
Roberto González-Pizarro
ASAmelia Silva
Amelia Silva
Eliana B. SoutoEliana B. Souto
Eliana B. Souto
Glaucoma constitutes the second cause of blindness worldwide and it is considered a neurodegenerative disorder. In this sense, Alzheimer’s disease, which is the most common type of dementia, also causes neurodegeneration. The association between both diseases remains unknown although it has been hypothesised that a possible connection might exist and it will be analysed throughout the review. In this sense, nanoparticulate systems and specially, lipid nanoparticles could be the key for effective neuroprotection. Lipid nanoparticles are the most recent type of drug nanoparticulate systems. These nanoparticles have shown great potential to encapsulate hydrophobic drugs increasing their bioavailability and being able to deliver them to the target tissue. In addition, they have shown great potential for ocular drug delivery. This review explores the most recent strategies employing lipid nanoparticles for AD and glaucoma.